CGC · Canopy Growth Corporation · Stock research

Current Thesis

The tradeable narrative is federal cannabis rescheduling, and it is dissipating in real time. The DEA's expedited hearing on moving adult-use marijuana from Schedule I to Schedule III opened 2026-06-29 and closes 2026-07-15 (DEA press release, 2026-06-25) but with no live closing arguments and no verdict at the gavel. Designated parties file written briefs, then an administrative law judge issues a recommendation on an undated later schedule (Vicente LLP). All seven DEA-designated hearing participants oppose rescheduling, and the DEA opened aggressively, leading with an FDA witness cross-examined only by anti-rescheduling parties (Cannabis Business Times, 2026-07). The binary most retail is trading around has no crisp resolution date the event that was supposed to re-rate the sector comes and goes 2026-07-15 leaving only a paper trail. Canopy, ~$0.97 (2026-07-10) and ~15% off its $0.84 low, is a high-beta Canadian proxy onto a US adult-use catalyst it collects no direct benefit from. Low conviction, and the reason to own it is thinning by the day.

Bullish and bearish views on Canopy Growth Corporation

The model's bull view on Canopy Growth Corporation (CGC), in brief: Hearing is live now: the DEA formal rescheduling hearing runs 2026-06-29 → 2026-07-15 and, for the first time, weighs adult-use marijuana for Schedule III rather than medical-only (DEA, 2026-06-25; Federal Register, 2026-04-28). The bear view: The catalyst produces no verdict: the 2026-07-15 close ends the evidentiary phase only; briefs follow, then an undated ALJ recommendation, then a DEA final rule that "will certainly be contested" a prior rescheduling fight ran nearly a decade to a DC Circuit ruling (Marijuana… Both cases follow in full.

Bull Case

• Hearing is live now: the DEA formal rescheduling hearing runs 2026-06-29 → 2026-07-15 and, for the first time, weighs adult-use marijuana for Schedule III rather than medical-only (DEA, 2026-06-25; Federal Register, 2026-04-28). A constructive ALJ recommendation, whenever it lands, re-rates the entire cannabis basket, and a sub-$1 retail-heavy float gaps hard on rescheduling headlines.
• The April 2026 order broke a 50-year seal: DOJ/DEA moved FDA-approved marijuana drug products and state-licensed medical marijuana to Schedule III on 2026-04-28 the first Schedule I exit in five decades. Direction of travel is set; only the adult-use leg is unresolved.
• Balance sheet repaired: FY2026 closed in a net cash position of +$131.3M, a ~$304M swing from net debt a year earlier, after a January 2026 recapitalization (Q4 FY2026 release, 2026-06-15). Free cash outflow was cut to $69.1M; management guided to positive adjusted EBITDA during FY2027.
• Top line growing again: Q4 consolidated net revenue $71.2M, +10% YoY, with Canada medical +27% and international cannabis +68% YoY; the MTL Cannabis acquisition (closed 2026-03-16) makes Canopy the largest Canadian medical cannabis company by revenue.
• Firmer near-term tape: shares are up ~8% into early July on legalization optimism, holding a $0.92–$1.06 band (MarketBeat, 2026-07-10) rather than pressing the $0.84 low.

Bear Case

• The catalyst produces no verdict: the 2026-07-15 close ends the evidentiary phase only; briefs follow, then an undated ALJ recommendation, then a DEA final rule that "will certainly be contested" a prior rescheduling fight ran nearly a decade to a DC Circuit ruling (Marijuana Moment; Gibson Dunn, 2026). The event much of the float is positioned into delivers no decision and no cash-flow payoff on 2026-07-15.
• The panel is stacked against it: all seven DEA-designated participants oppose rescheduling, and the DEA opened with an FDA witness cross-examined only by anti-rescheduling parties (Cannabis Business Times; GreenState, 2026-07). The record being built skews toward keeping adult-use in Schedule I.
• Wrong vehicle: 280E tax relief from adult-use rescheduling accrues to US plant-touching MSOs (Trulieve TCNNF, Green Thumb GTBIF, Curaleaf CURLF), not a Canadian LP whose US exposure runs indirectly through Canopy USA (Acreage/Wana/Jetty). Trulieve's 2026-06-10 NYSE listing is exactly the institutional-access story CGC sits outside of.
• Dilution caps upside: ~378M shares outstanding, +163% YoY through serial ATM raises and the stock-funded MTL deal. Each rally has funded the next raise; a favorable headline gets absorbed into a larger base.
• Bottom line still deeply negative: Q4 EPS −$0.29 vs −$0.06 consensus (2026-06-15); The business remains cash-burning even as revenue grows, and one independent model pins fair value near $0.72 against a ~$0.97 tape.

Setup & Price Structure

Near $0.97 (2026-07-10), CGC sits ~15% above its $0.84 52-week low and ~59% below the $2.38 high, with no reclaimed moving average and no higher-low base a sub-$1 penny structure that trades on headlines, not trend. The ~8% early-July pop tightened the range to roughly $0.92–$1.06 — but did nothing to repair the broken longer-term structure. This is a low-priced, high-beta event proxy: violent on rescheduling headlines in either direction, mean-reverting once the headline fades. Short interest is modest (~6% of float, MarketBeat May 2026), making this a binary-event option rather than a squeeze vehicle do not model a gamma or short-cover leg. With the catalyst resolving into written briefs instead of a decision, the asymmetry that would justify chasing strength is absent; any bounce here is a headline spike to fade, with no trend underneath to ride.

Catalyst Calendar (next 30 days)

• No FDA/PDUFA, analyst-day, or index-rebalance events in the window.

Elapsed catalysts

• 2026-07-15 DEA rescheduling hearing concludes. Evidentiary phase ends; no closing arguments, no verdict. Post-hearing written briefs follow (DEA; Vicente LLP). This is the only dated cannabis event in the window, and it resolves nothing on its own. _(passed 4d ago)_
• Undated, post-2026-07-15 administrative law judge issues a formal recommendation on adult-use Schedule III. No fixed date; "expedited" per the administration directive but historically slow. This is the real decision and it is NOT in the next 30 days. _(passed 4d ago)_
• ~early-to-mid August 2026 (est.) Q1 FY2027 earnings (quarter ended 2026-06-30). Outside the 30-day window; first read on whether MTL integration and the recapitalized balance sheet slow the cash burn. _(passed 19d ago)_

What Would Change Our Mind

• Upside: an administrative-law-judge recommendation (whenever it is dated) that explicitly folds adult-use marijuana into Schedule III, or a DEA signal during briefing that it will not contest the broader reschedule either re-rates the sector and would justify initiating on a fresh setup, ideally on a 20-EMA reclaim rather than a headline gap. A clean higher-low base built above $1.00 with the theme re-accelerating would upgrade this from a fading event-option to a genuine setup.
• Downside / thesis break: a daily close below $0.84 (a fresh 52-week low); or the 2026-07-15 close arriving with the record clearly skewed against adult-use and the ALJ decision slipping undated into H2 2026, flipping the theme toward DEAD. A US-listed MSO (Trulieve, Green Thumb) taking sector leadership while CGC lags would confirm the wrong-vehicle read.

Correlation Notes

Cleaner expressions of the same catalyst are the US plant-touching MSOs Trulieve (TCNNF), Green Thumb (GTBIF), Curaleaf (CURLF) plus the AdvisorShares MSOS ETF; those capture 280E relief directly, CGC does not. On any rescheduling headline, expect CGC to move with the basket but with more noise, given its lower price and thinner quality of exposure. Idiosyncratic drivers are Canadian adult-use and medical volumes, ATM issuance cadence (dilution), and MTL Cannabis integration. Beta to broad indices (SPY/QQQ) is low; the dominant factor is binary US cannabis-policy headlines, which cluster the whole group's moves regardless of company-specific news.